Clinical Trial

Testing Experimental HIV Medication in Healthy Subjects

Study Description

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

This a phase 1 first-in-human clinical trial to evaluate the safety, tolerability, and immunogenicity of BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in up to 60 healthy adult HIV-uninfected volunteers.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Biological - BG505 SOSIP.664 gp140, adjuvanted

Dosage of 30ug, Intramuscular administration

Biological - BG505 SOSIP.664 gp140, adjuvanted

Dosage of 100ug, Intramuscular administration

Biological - BG505 SOSIP.664 gp140, adjuvanted

Dosage of 300ug, Intramuscular administration

Biological - Placebo

Tris-NaCl Diluent

Additional Information

Official Study Title

A Randomized, Double-blinded, Placebo-controlled, Dose-escalation Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV Envelope Protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in Healthy, HIV-1 Uninfected Adults

Clinical Trial ID

NCT03699241

ParticipAid ID

en5ORd